Stockscreener 앱 받기
13.52
0.29%
-0.04
시간 외 거래:
13.59
0.07
+0.52%
전일 마감가:
$13.56
열려 있는:
$13.53
하루 거래량:
41,789
Relative Volume:
0.54
시가총액:
$255.27M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-12.09%
1개월 성능:
+21.47%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$12.82
$14.14
1주일 범위
$12.82
$15.43
52주 변동 폭
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
명칭
Aardvark Therapeutics Inc
전화
(858) 225-7696
주소
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
AARD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
13.52 | 255.27M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-10 | 개시 | BofA Securities | Buy |
| 2025-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-10 | 개시 | Morgan Stanley | Overweight |
| 2025-03-10 | 개시 | RBC Capital Mkts | Outperform |
Aardvark Therapeutics Inc 주식(AARD)의 최신 뉴스
Wall Street Zen Downgrades Aardvark Therapeutics (NASDAQ:AARD) to Sell - Defense World
Cantor Fitzgerald Predicts AARD FY2026 Earnings - Defense World
Aardvark Therapeutics (NASDAQ:AARD) Upgraded to “Hold” at Wall Street Zen - Defense World
Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet - MSN
Aardvark Therapeutics (NASDAQ:AARD) Rating Lowered to Sell at Wall Street Zen - Defense World
Aardvark Therapeutics reshuffles leadership amid Phase 3 study - Investing.com Australia
Aardvark Therapeutics appoints Timothy Kieffer as CSO, Danny Villeneuve as CCO - TipRanks
Aardvark Therapeutics reshuffles leadership amid Phase 3 study By Investing.com - Investing.com UK
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions - The Manila Times
Equities Analysts Set Expectations for AARD FY2025 Earnings - Defense World
Aardvark Therapeutics, Inc. Announces Executive Changes - MarketScreener
Royal Bank of Canada Lowers Aardvark Therapeutics (NASDAQ:AARD) Price Target to $20.00 - Defense World
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - The Manila Times
Aardvark Therapeutics to Present at Upcoming Investor Conferences in May - The Manila Times
Aardvark Therapeutics, Inc. to Present at Key Healthcare Conferences in May 2025 - Nasdaq
Aardvark Therapeutics Inc’s Market Journey: Closing Strong at 7.79, Up 6.86 - DWinneX
Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Community Health (CYH) and Integer Holdings (ITGR) - The Globe and Mail
Aardvark Therapeutics (NASDAQ:AARD) Trading Up 7.6% – What’s Next? - Defense World
Why United Airlines Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings - insights.citeline.com
Aardvark Therapeutics (NASDAQ:AARD) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock - Investing.com Australia
RBC Capital maintains $21 target on Aardvark Therapeutics stock - Investing.com Australia
RBC Capital maintains $21 target on Aardvark Therapeutics stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock By Investing.com - Investing.com South Africa
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights - The Manila Times
Aardvark Therapeutics Inc. (AARD) reports earnings - qz.com
Bank of America Boosts Aardvark Therapeutics (NASDAQ:AARD) Price Target to $26.00 - Defense World
BofA lifts Aardvark Therapeutics target to $26, maintains Buy By Investing.com - Investing.com Canada
Positive Outlook for Aardvark Therapeutics Amid Favorable Regulatory and Market Conditions - TipRanks
BofA lifts Aardvark Therapeutics target to $26, maintains Buy - Investing.com Australia
Aardvark Therapeutics price target raised to $26 from $22 at BofA - TipRanks
Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (NASDAQ:SLNO) - Seeking Alpha
Aardvark Therapeutics, Inc.’s Quiet Period Will End on March 25th (NASDAQ:AARD) - Defense World
Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month - Insider Monkey
Top 10 Insider Purchases Last Month - Insider Monkey
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Royal Bank of Canada - Defense World
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Morgan Stanley - Defense World
BofA sets Aardvark Therapeutics stock with $22 target By Investing.com - Investing.com Australia
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Analysts at Cantor Fitzgerald - Defense World
BofA Initiates Aardvark Therapeutics at Buy With $22 Price Target -March 10, 2025 at 10:01 am EDT - Marketscreener.com
RBC Capital sets Aardvark Therapeutics at Outperform - Investing.com
This Pulmonx Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
RBC Capital sets Aardvark Therapeutics at Outperform By Investing.com - Investing.com South Africa
Aardvark Therapeutics initiated with an Overweight at Cantor Fitzgerald - TipRanks
Aardvark Therapeutics Inc (AARD) 재무 분석
Aardvark Therapeutics Inc (AARD)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Aardvark Therapeutics Inc 주식 (AARD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lee Tien-Li | Chief Executive Officer |
Feb 14 '25 |
Buy |
16.00 |
16,542 |
264,672 |
1,496,175 |
| Sun Nelson | Chief Financial Officer |
Feb 14 '25 |
Buy |
16.00 |
10,000 |
160,000 |
99,484 |
| Cormorant Asset Management, LP | Former 10% Owner |
Feb 14 '25 |
Buy |
16.00 |
187,500 |
3,000,000 |
987,689 |
1.45%
0.86%
자본화:
|
볼륨(24시간):